<DOC>
	<DOC>NCT02624869</DOC>
	<brief_summary>To describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab (AMG 145) when added to standard of care in pediatric subjects 10 to 17 years of age with HeFH or HoFH.</brief_summary>
	<brief_title>Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Subjects with HeFH: Completed Study 20120123 while still on assigned investigational product and did not experience a treatment‑related serious adverse event Subjects with HoFH: Male or female, ≥ 10 to ≤ 17 years of age at time of enrollment Diagnosis of HoFH On a lowfat diet and receiving background lipidlowering therapy Lipidlowering therapy unchanged for ≥ 4 weeks prior to LDLC screening; fibrates must be stable for at least 6 weeks prior to screening. Fasting LDLC at screening ≥ 130 mg/dL (3.4 mmol/L) Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) All Subjects Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treament on another investigational device or drug study(s); except Study 20120123 Subjects with HoFH: Moderate to severe renal dysfunction Active liver disease or hepatic dysfunction, CK &gt; 3 times the ULN at screening</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>PCSK9 mutations</keyword>
	<keyword>Severe Familial Hypercholesterolemia</keyword>
	<keyword>evolocumab</keyword>
	<keyword>Repatha</keyword>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
	<keyword>Homozygous Familial Hypercholesterolemia</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Paediatric</keyword>
</DOC>